Dr. Gerhard Hager

CEO
The NCD Company, Germany
Gerhard is a non-clinical development expert with extensive experience in design and management of preclinical programs. He has a broad expertise in early drug development ranging from small molecules to biologics, vaccines to ATMPs. After almost 20 years in the CRO and Pharma industry he is today director of The NCD Company that provides non-clinical drug development services to the pharmaceutical industry. Gerhard holds a PhD from the Ludwig-Maximilians-University Munich. After 10 years in Neuroscience he started his industrial career by leading a full service non-clinical CRO for Pharmacology, ADME, Bioanalytics and Toxicology. In 2015 he left the CRO and became Head of Toxicology at Baxalta Innovations GmbH (later Shire PLC). Gerhard has extensive experience in the interdisciplinary design and management of early drug development programs integrating research, pharmacology, ADME and toxicology for different indications such as tumor, inflammation and hematology and substance classes (e.g. small molecules, biologics, biosimilars, antibodies, cell and gene therapy, vaccines). As facility manager for pharmacological research and GLP compliant work in different countries and leading outsourcing in the pharmaceutical industry he is familiar with all aspects of subcontracting in drug development. The NCD Company provides now all kinds of non-clinical services from CRO identification and management of single studies up to the fully integrated management of non-clinical drug development programs including preparation of submission documents to biotech companies, research institutes and the pharmaceutical industry.

Events/Masterclasses Dr. Gerhard Hager is currently speaking at

Pharma

Toxicology, ADME & Early Drug Development Plan
23 - 24 March 2023
Rome, Italy | Online Live Stream 9:00 CET – 17:00 CET
Building an Integrated Safety Testing Strategy based on ADME and Toxicology. The purpose of this Toxicology, ADME & Early Drug Development Plan is to understand the concept of a combined ADME-Toxicology approach.

Are you interested in a custom-made event with this trainer?

Contact us to Request more information about your custom-made Corporate Learning program.

REQUEST MORE INFORMATION

Dr. Gerhard Hager
CEO
The NCD Company, Germany
Gerhard is a non-clinical development expert with extensive experience in design and management of preclinical programs. He has a broad expertise in early drug development ranging from small molecules to biologics, vaccines to ATMPs. After almost 20 years in the CRO and Pharma industry he is today director of The NCD Company that provides non-clinical drug development services to the pharmaceutical industry. Gerhard holds a PhD from the Ludwig-Maximilians-University Munich. After 10 years in Neuroscience he started his industrial career by leading a full service non-clinical CRO for Pharmacology, ADME, Bioanalytics and Toxicology. In 2015 he left the CRO and became Head of Toxicology at Baxalta Innovations GmbH (later Shire PLC). Gerhard has extensive experience in the interdisciplinary design and management of early drug development programs integrating research, pharmacology, ADME and toxicology for different indications such as tumor, inflammation and hematology and substance classes (e.g. small molecules, biologics, biosimilars, antibodies, cell and gene therapy, vaccines). As facility manager for pharmacological research and GLP compliant work in different countries and leading outsourcing in the pharmaceutical industry he is familiar with all aspects of subcontracting in drug development. The NCD Company provides now all kinds of non-clinical services from CRO identification and management of single studies up to the fully integrated management of non-clinical drug development programs including preparation of submission documents to biotech companies, research institutes and the pharmaceutical industry.
Dr. Gerhard Hager
Description